MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
Price history
Daily open, high, low, close and volume
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Daily prices are not in StockData yet. This table fills in once an end-of-day price source is connected. | ||||||
Stock splits
From SEC filings
| Date | Ratio | Effect on per-share figures |
|---|---|---|
| Mar 26, 2009 | 2-for-1 | Earlier per-share figures divided by 2 |
| Sep 12, 2000 | 2-for-1 | Earlier per-share figures divided by 2 |